Daniel J. Mitchell - Dec 15, 2022 Form 4 Insider Report for ARCA biopharma, Inc. (ABIO)

Role
Director
Signature
/s/ C. Jeffrey Dekker, Attorney-in-Fact
Stock symbol
ABIO
Transactions as of
Dec 15, 2022
Transactions value $
$0
Form type
4
Date filed
12/19/2022, 03:24 PM
Next filing
Jan 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABIO Common Stock 611 Dec 15, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABIO Stock Option (right to buy) Award $0 +6K $0.00 6K Dec 15, 2022 Common Stock 6K $2.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of December 15, 2022. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.